Stuart H Isaacson MD FAAN

Neurology•Boca Raton, FL

Movement Disorder

Director and Founder Parkinson's Disease and Movement Disorders Center of Boca Raton

Join to View Full Profile

Parkinson’s Disease and Movement Disorders Center of Boca Raton951 Nw 13th St, Bldg 5-EBoca Raton, FL 33486
Phone+1 561-392-1818
Fax+1 561-392-8989

Summary

Stuart H. Isaacson, MD, FAAN is the Director of the Parkinson’s Disease and Movement Disorders Center of Boca Raton in Florida. Dr. Isaacson has been involved in over 250 clinical trials, and has served as Principal Investigator and on steering committees for many therapeutic development programs, and has authored or co-authored over 200 journal articles, abstracts, and book chapters.

Education & Training

Icahn School of Medicine at Mount SinaiFellowship, Neuromuscular Medicine (Neurology), 1995 - 1996
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Neurology, 1989 - 1992
Icahn School of Medicine at Mount Sinai/Morningside/WestInternship, Internal Medicine, 1988 - 1989
Northwestern University The Feinberg School of MedicineClass of 1988

Certifications & Licensure

NY State Medical License 1989 - 2027
FL State Medical License 1997 - 2026
American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014-2024
Super Doctor SuperDoctors.com

Clinical Trials

Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression Start of enrollment: 2010 Jun 01
Completed
Phase 2
A Post Marketing Observational Study of Activities of Daily Living in Advanced Parkinson's Disease Patients With Early Troublesome Motor Fluctuations and Treated With Duodopa - a Multi-country Study Start of enrollment: 2013 Feb 01
Completed
Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT) Start of enrollment: 2012 Dec 01
Completed
Phase 4
A Study to Examine APL-130277 in Patients With Parkinson's Disease Start of enrollment: 2014 Aug 31
Completed
Phase 2
Evaluation of Safety and Tolerability of ENT-01 for the Treatment of Parkinson's Disease Related Constipation Start of enrollment: 2017 May 11
Completed
Phase 1, Phase 2
The Effect of Parkinson Kinetigraph Recordings on the Management and Outcome in Parkinson's Disease Start of enrollment: 2017 Apr 30
Completed
Not Applicable
A Phase 3 Study With P2B001 in Subjects With Early Parkinson's Start of enrollment: 2018 Jan 19
Completed
Phase 3
Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide) Start of enrollment: 2017 Nov 30
Completed
Fixed-Dose Trial in Early Parkinson's Disease (PD) Start of enrollment: 2019 Dec 13
COMPLETED
PHASE3
Roles: Contact
Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations (TEMPO-3) Start of enrollment: 2020 Sep 23
COMPLETED
PHASE3
Open-label Trial in Parkinson's Disease (PD) Start of enrollment: 2021 Feb 24
Enrolling by invitation
Phase 3
Roles: Contact
A Study of AP-CD/LD in Fluctuating Parkinson's Disease Patients Who Completed IN 11 004 Start of enrollment: 2016 Jul 01
Unknown status
Phase 3
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Long-Term Safety and Efficacy of Repeated Cycles of RimabotulinumtoxinB in the Treatment of Chronic Sialorrhea: Results of the OPTIMYST Trial.
Rajesh Pahwa, Eric Molho, Mark Lew, Khashayar Dashtipour, Ramon A Gil
Neurology and Therapy. 2025-08-01
1 citations
Efficacy and Safety of Foslevodopa/Foscarbidopa Monotherapy in Patients with Parkinson's Disease.
Jason Aldred, Manon Bouchard, Juan Carlos Martínez-Castrillo, Michael J Soileau, Amy M Spiegel
Movement Disorders Clinical Practice. 2025-07-30
Safety and Efficacy of Istradefylline in Parkinson's Disease Patients With and Without Preexisting Dyskinesia: Pooled Analysis of 8 Randomized Controlled Trials.
Nobutaka Hattori, Lawrence Elmer, Stuart H Isaacson, Rajesh Pahwa, Olivier Rascol
Journal of Movement Disorders. 2025-07-01

Press Mentions

Cerevance to Present Phase 2 Solengepras Data at Parkinson’s CongressSeptember 24th, 2025
Supernus Announces FDA Approval of ONAPGO™ (Apomorphine Hydrochloride) for Parkinson’s DiseaseFebruary 4th, 2025
BeyoND Phase 2b Data Indicates ND0612 Has a Positive Long-Term Safety Profile for People with Parkinson's DiseaseApril 4th, 2022
Join now to see all